Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Chinese Journal of Information on Traditional Chinese Medicine ; (12): 34-38, 2018.
Article in Chinese | WPRIM | ID: wpr-707085

ABSTRACT

Objective To discuss the clinical efficacy of Bushen Huayu Sanjie Prescription for the treatment of deficiency of both qi and yin and blood stasis in patients with stage Ⅳ of type 2 diabetic nephropathy. Methods Totally 90 patients with stage Ⅳ of type 2 diabetic nephropathy were randomly divided into treatment group and control group, with 45 cases in each group. The control group was given Western routine therapy, such as low-protein diet, control of body mass, hypoglycemic, antihypertensive, lipid-lowering, anticoagulation, and microcirculation, etc. On the basis of control group,treatment group was given Bushen Huayu Sanjie Prescription,one dosage per day,twice a day, orally. The treatment for both groups lasted for three months. TCM symptom scores, blood glucose, blood lipids, renal function, 24-hour urinary total protein (UTP), and serum transforming growth factor-β1 (TGF-β1) and C-reactive protein (CRP) levels before and after treatment in the two groups were observed. Results The total effective rate of clinical efficacy and TCM efficacy of the treatment group were 80.00% and 84.44%, respectively, and the control group was 62.22%. The treatment group was superior to the control group (P<0.05). Compared with before treatment, TCM symptom scores, blood glucose, blood lipids, renal function, UTP, serum CRP, and TGF-β1 were significantly improved in the two groups (P<0.05). The scores of TCM symptoms, TGF-β1, CRP and UTP in the treatment group were better than that in the control group (P<0.05). Conclusion Bushen Huayu Sanjie Prescription combined with Western routine therapy for the treatment of deficiency of both qi and yin and blood stasis in patients with stage Ⅳ of type 2 diabetic nephropathy has good clinical efficacy, which can delay disease progression by reducing TGF-β1 and CRP, inhibiting renal interstitial fibrosis, and decreasing urinary protein excretion.

SELECTION OF CITATIONS
SEARCH DETAIL